{"type":"trials","record":{"id":33595,"source_id":"clinicaltrials-gov","external_id":"NCT02154971","title":"Assessment of Age-related Hearing Loss in HIV-1 Patients","brief_summary":"The ageing process is known to be accelerated in HIV-infected patients, compared to the general population. Normal age-related hearing loss (presbyacusia) is a frequent phenomenon, affecting more than 70% of people above 65 years. It is believed to be mostly the consequence of a mitochondrial damage caused by oxidative stress. Risk factors for accelerated age-related hearing loss are present in many HIV-infected patients : chronic inflammation, smoking, diabetes, etc. The global aim is to measure the prevalence of presbyacusia in a well controlled HIV positive population in France, and to compare it to HIV negative controls matched for age and sex. 90 HIV positive patients and 90 age- and sex- matched HIV negative controls will undergo a screening for presbyacusia (pure-tone, speech and evoked-response audiometry). We expect to find an increased prevalence of presbyacusia in HIV-infected patients, as compared to controls matched for age and sex.","overall_status":"Completed","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","enrollment":206,"countries":["France"],"start_date":"2013-11-18","completion_date":"2019-02-26","last_update_date":"2020-09-16","source_url":"https://clinicaltrials.gov/study/NCT02154971","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:20:11.10691+00:00","last_seen_at":"2026-09-25T06:25:04.647+00:00","metadata":{"sex":"ALL","acronym":"HELO","age_range":"40 Years","comparator":null,"organization":"Fondation Ophtalmologique Adolphe de Rothschild","interventions":[],"registry_source":"ClinicalTrials.gov","outcome_measures":["hearing loss at several frequencies — Baseline","threshold for speech intelligibility — Baseline","Proportion of patients with neuropathic hearing loss — Baseline","Interval I-V on the evoked-response audiogram — Baseline","Maximum speech intelligibility — Baseline","Proportion of patients with age-related hearing loss — Baseline"],"design_description":null,"source_has_results":false},"controlled_terms":["HIV Seropositivity"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Title contains controlled term: age-related hearing loss.","quality_checked_at":"2026-09-25T06:25:07.732232+00:00","duplicate_cluster_key":"id:nct02154971","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2013-11-18 to 2019-02-26","comparator":null,"confidence":"structured-source","population":"ALL · 40 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:25:04.667Z","intervention":[],"participants":206,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["hearing loss at several frequencies — Baseline","threshold for speech intelligibility — Baseline","Proportion of patients with neuropathic hearing loss — Baseline","Interval I-V on the evoked-response audiogram — Baseline","Maximum speech intelligibility — Baseline","Proportion of patients with age-related hearing loss — Baseline"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"hearing-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related hearing loss.","Abstract contains controlled term: age-related hearing loss.","Title supplies longevity context: age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["title","abstract","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Hearing ageing","slug":"hearing-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/33595","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}